Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Retrospective/Prospective, open-label study using sofosbuvir based DAA therapy to treat
HIV/HCV coinfected pre or post liver transplant participants
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Columbia University Georgetown University Icahn School of Medicine at Mount Sinai Johns Hopkins University National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health Clinical Center (CC) University of Maryland University of Maryland, College Park University of Pennsylvania
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir